CRISPR Therapeutics AG (CRSP)
55.43
-0.01
(-0.02%)
USD |
NASDAQ |
Oct 02, 16:00
55.33
-0.10
(-0.18%)
After-Hours: 20:00
CRISPR Therapeutics Profit Margin (Quarterly) : -895.3% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -895.3% |
| March 31, 2026 | -8.43K% |
| December 31, 2025 | -15.12K% |
| September 30, 2025 | -11.97K% |
| June 30, 2025 | -23.38K% |
| March 31, 2025 | -15.72K% |
| December 31, 2024 | -104.5% |
| September 30, 2024 | -14.28K% |
| June 30, 2024 | -24.45K% |
| March 31, 2024 | -23.13K% |
| December 31, 2023 | 44.41% |
| September 30, 2023 | |
| June 30, 2023 | -111.1% |
| March 31, 2023 | -53.06% |
| December 31, 2022 | -1.84M% |
| September 30, 2022 | -185.7K% |
| June 30, 2022 | -117.6K% |
| March 31, 2022 | -19.07K% |
| December 31, 2021 | -1.10K% |
| September 30, 2021 | -15.43K% |
| June 30, 2021 | 84.29% |
| Date | Value |
|---|---|
| March 31, 2021 | -20.99K% |
| December 31, 2020 | -28.93K% |
| September 30, 2020 | -62.46K% |
| June 30, 2020 | -181.0K% |
| March 31, 2020 | -44.41K% |
| December 31, 2019 | 39.66% |
| September 30, 2019 | 65.32% |
| June 30, 2019 | -16.89K% |
| March 31, 2019 | -14.76K% |
| December 31, 2018 | -41.38K% |
| September 30, 2018 | -9.01K% |
| June 30, 2018 | -3.53K% |
| March 31, 2018 | -2.08K% |
| December 31, 2017 | 0.43% |
| September 30, 2017 | -1.04K% |
| June 30, 2017 | -623.0% |
| March 31, 2017 | -794.5% |
| December 31, 2016 | |
| September 30, 2016 | -948.6% |
| June 30, 2016 | -2.16K% |
| March 31, 2016 | -1.77K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 32.89% |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 13.90% |
| AC Immune SA | 12.40% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -24.76% |
| Return on Assets | -18.93% |
| Return on Invested Capital | -19.94% |
| Gross Profit Margin (Quarterly) | -337.8% |
| Operating Margin (Quarterly) | -1.13K% |
| Return on Net Operating Assets | -181.9% |